Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2012 | 11:51pm CEST

--FDA approves new Protalix/Pfizer treatment for a type of Gaucher disease

--Elelyso approved for use in adults; will compete with Shire, Sanofi products

--People with Gaucher disease lack glucocerebrosidase, which causes an accumulation of a fatty substance inside cells

(Updates with additional information about Elelyso clinical studies starting in eighth paragraph. )

   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration on Tuesday approved a new treatment developed by Protalix BioTherapeutics Inc. (PLX, PLX.TV) for adults with a type of Gaucher disease, a rare genetic disorder.

The treatment, taliglucerase alfa, will be sold in the U.S. under the brand name Elelyso by Pfizer Inc. (>> Pfizer Inc.).

Pfizer also will sell the drug in most places outside the U.S. The drug, which is the first plant-derived cell-based enzyme replacement, replaces an enzyme called glucocerebrosidase in people with type 1 Gaucher disease. Elelyso is produced using genetically engineered carrot cells.

People with Gaucher disease lack glucocerebrosidase, which causes an accumulation of a fatty substance inside cells. The fatty accumulation can lead to enlargement and malfunctioning of the liver, spleen, bone marrow and occasionally, the lung, kidney, and intestine. About 6,000 people in the U.S. have type 1 Gaucher disease, according to the FDA.

Pfizer and Protalix have already been making Elelyso available to some Gaucher disease patients as part of an early access program because of manufacturing issues at Genzyme, a unit of Sanofi SA (SNY, SAN.FR), which makes another glucocerebrosidase-enzyme replacement product, Cerezyme. Earlier this year, Genzyme said the manufacturing problems had been fixed and that the company is able to make enough of the product to supply current patients in the U.S.

Shire PLC (SHPGY, SHP.LN), which also makes a Gaucher disease treatment, Vpriv, has said inventories of the product will be "below target levels" until the FDA signs off on a second manufacturing plant in the U.S. However, the company also said it has the capacity to meet anticipated demand for Vpriv. Cerezyme and Vpriv are approved for use in children as well as adults.

Officials from Pfizer and Protalix said the companies have already built enough inventory of Elelyso to supply to patients for at least 24 months.

Elelyso is an infusion that is administered by health-care professionals every other week.

The FDA said the approval of Elelyso was based on two studies involving 56 patients with type 1 Gaucher disease. One study looked at 31 patients who had not previously received enzyme-replacement therapy. The study showed Elelyso reduced the size of patients' spleens by an average of 29% to 40%, depending on the dose of the drug, after nine months of treatment. The other study involved 25 patients who were switched from Cerezyme. The FDA said that study showed Elelyso was effective in maintaining spleen and liver volumes, blood platelet counts and hemoglobin levels during a nine-month evaluation period.

The agency said the most common side effects were infusion reactions and allergic reactions.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; [email protected]

Stocks mentioned in the article : Pfizer Inc.
Stocks mentioned in the article
ChangeLast1st jan.
PROTALIX BIOTHERAPEUTICS INC 0.37% 0.4316 Delayed Quote.-34.72%
SANOFI 0.64% 65.84 Real-time Quote.-8.95%
SHIRE 0.95% 3965 Delayed Quote.0.77%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
10:25aPFIZER : Invites Public to Listen to Webcast of April 26 Annual Meeting of Share..
AQ
10:24aONCONOVA THERAPEUTICS : Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at Amer..
AQ
09:54aMERCK AND : adds affinity optimization to nanoscale synthesis system
AQ
04/24Women's Health Market Analysis on Segment, Trend, Growth, Volume, Size, Globa..
AQ
04/24Biocon to gain as Pfizer’s Herceptin biosimilar delayed further
AQ
04/24PFIZER : hits stumbling block on Herceptin rival, but wins breakthrough status o..
AQ
04/24PFIZER : Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococca..
AQ
04/24PFIZER : MYLOTARG Approved in the EU for the Treatment of Previously Untreated, ..
AQ
04/24PFIZER : CD33-positive AML drug approved in Europe
AQ
04/23PFIZER : Neuropathy Pain Treatment Market Global Analysis 2012-2017 and Forecast..
AQ
More news
News from SeekingAlpha
2015Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update 
2015Antibiotics Stocks To Benefit From 21st Century Cures Act 
2015ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case 
2015DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb 
2015Pfizer's GL-2045 an Orphan Drug for CIDP 
Financials ($)
Sales 2018 54 460 M
EBIT 2018 20 816 M
Net income 2018 12 632 M
Debt 2018 23 675 M
Yield 2018 3,71%
P/E ratio 2018 17,01
P/E ratio 2019 15,55
EV / Sales 2018 4,45x
EV / Sales 2019 4,24x
Capitalization 219 B
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 40,1 $
Spread / Average Target 8,2%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC218 908
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.13%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398